bluebird bio, Inc. (NASDAQ:BLUE)’s share price shot up 4.1% during trading on Friday . The company traded as high as $142.40 and last traded at $135.30. 713,428 shares traded hands during trading, a decline of 25% from the average session volume of 947,998 shares. The stock had previously closed at $141.15.

A number of brokerages have commented on BLUE. Leerink Swann reissued an “outperform” rating and set a $120.00 target price on shares of bluebird bio in a report on Saturday. Cantor Fitzgerald reissued a “sell” rating and set a $39.00 target price on shares of bluebird bio in a report on Thursday. Barclays PLC began coverage on bluebird bio in a report on Wednesday, September 6th. They set an “overweight” rating and a $151.00 target price for the company. Wells Fargo & Company reissued an “outperform” rating and set a $158.00 target price (up previously from $134.00) on shares of bluebird bio in a report on Tuesday, September 5th. Finally, Wedbush reissued an “outperform” rating and set a $135.00 target price (up previously from $121.00) on shares of bluebird bio in a report on Friday, September 1st. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and thirteen have assigned a buy rating to the company’s stock. bluebird bio currently has an average rating of “Hold” and an average target price of $109.61.

The firm’s market capitalization is $6.26 billion. The firm has a 50-day moving average of $108.37 and a 200 day moving average of $97.10.

bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.66) by ($0.07). The business had revenue of $16.70 million during the quarter, compared to analyst estimates of $6.29 million. bluebird bio had a negative net margin of 1,080.59% and a negative return on equity of 32.19%. The company’s revenue was up 977.4% on a year-over-year basis. During the same quarter last year, the firm posted ($1.59) earnings per share. Equities research analysts anticipate that bluebird bio, Inc. will post ($6.84) EPS for the current fiscal year.

In other bluebird bio news, insider David Davidson sold 5,000 shares of the business’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $105.28, for a total value of $526,400.00. Following the completion of the transaction, the insider now directly owns 22,177 shares in the company, valued at approximately $2,334,794.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director James Mandell sold 1,000 shares of the business’s stock in a transaction on Monday, August 14th. The shares were sold at an average price of $95.95, for a total value of $95,950.00. Following the completion of the transaction, the director now owns 1,000 shares of the company’s stock, valued at $95,950. The disclosure for this sale can be found here. Insiders sold a total of 133,829 shares of company stock valued at $16,006,899 over the last quarter. 3.90% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Hanseatic Management Services Inc. raised its holdings in bluebird bio by 0.3% in the 2nd quarter. Hanseatic Management Services Inc. now owns 10,436 shares of the biotechnology company’s stock valued at $1,096,000 after acquiring an additional 27 shares during the last quarter. Teacher Retirement System of Texas raised its holdings in bluebird bio by 1.7% in the 2nd quarter. Teacher Retirement System of Texas now owns 3,250 shares of the biotechnology company’s stock valued at $341,000 after acquiring an additional 53 shares during the last quarter. Martingale Asset Management L P raised its holdings in bluebird bio by 0.6% in the 1st quarter. Martingale Asset Management L P now owns 17,008 shares of the biotechnology company’s stock valued at $1,547,000 after acquiring an additional 100 shares during the last quarter. Cornerstone Capital Management Holdings LLC. raised its holdings in bluebird bio by 0.8% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 17,955 shares of the biotechnology company’s stock valued at $1,885,000 after acquiring an additional 140 shares during the last quarter. Finally, Prudential Financial Inc. raised its holdings in bluebird bio by 4.0% in the 2nd quarter. Prudential Financial Inc. now owns 3,882 shares of the biotechnology company’s stock valued at $408,000 after acquiring an additional 150 shares during the last quarter.

ILLEGAL ACTIVITY NOTICE: “bluebird bio, Inc. (BLUE) Shares Up -4.1%” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/bluebird-bio-inc-blue-shares-up-4-1/1599917.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.